Abstract
Non-small cell lung cancer (NSCLC) is the most common type of lung cancer. The overall 5-year survival rate of patients is extremely low and to find a new marker is urgently needed. Numerous studies indicate that long noncoding RNAs (lncRNAs) abnormally express in cancers. However, the results have been disputed, especially in the aspects of tumor prognosis. Therefore, we performed this meta-analysis to systematically summarize the relationship between lncRNAs expression and NSCLC. A total of 34 eligible studies including 30 on overall survival, 10 on progression-free survival and 23 on clinicopathological features were identified from the databases. Our results indicated that the levels of lncRNAs were associated with the overall survival (OS; hazard ratios [HR], 1.43; 95% confidence interval [95% CI], 1.17-1.76; P < 0.001). However, there was no relationship between lncRNAs and progression-free survival (PFS; hazard ratios [HR], 1.55; 95% confidence interval [95% CI], 0.91-2.63; P = 0.11). Moreover, lncRNAs were related to lymph node metastasis (odds ratios [OR], 1.70; 95% confidence interval [95% CI], 1.03-2.80; P = 0.04), while no association was observed with other characteristics. In conclusion, our present meta-analysis indicated that lncRNAs transcription levels may serve as a promising marker for prognosis of patients with NSCLC.
Highlights
Lung cancer is one of the most common malignant cancers worldwide, making up 18.2% of all malignant tumor mortality in the world [1, 2]
The results suggested that BRAF activated non-coding RNA (BANCR) could be a biomarker for poor prognosis of Non-small cell lung cancer (NSCLC) [19]
A total of 34 articles were in the current metaanalysis [3, 5, 16, 17, 19,20,21,22,23,24,25,26,27,28,29,30,31,32,33,34,35,36,37,38,39,40,41,42,43,44,45,46,47,48], including 30 on overall survival (OS) [3, 5, 16, 17, 19,20,21,22,23,24,25,26,27,28,29,30,31,32,33,34,35,36,37,38,39,40,41,42,43, 48], 10 on progressionfree survival (PFS) [17, 19, 20, 25, 36, 37, 44,45,46,47] and 23 on clinicopathological features[5, 16, 17, 19, 20, 22,23,24,25,26,27,28, 30, 32,33,34,35,36,37,38,39,40, 46]
Summary
Lung cancer is one of the most common malignant cancers worldwide, making up 18.2% of all malignant tumor mortality in the world [1, 2]. Non-small cell lung cancer (NSCLC) is the most common type, accounting for about 85% of lung cancer [3]. Despite the effective treatments for patients have obtained, including surgical resection, systemic chemotherapy and targeted drugs, the prognosis of NSCLC remains still poor and the 5-year survival rate is only 11-15%, because the patients were diagnosed at advanced stages [4,5,6]. In NSCLC researches, several genetic biomarkers have been used, including non-coding RNAs (ncRNAs). To identify sensitive and specific biomarkers for prognosis of patients with NSCLC is urgently needed
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
